title: Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial.
abstract: OBJECTIVE
  People with serious mental illness die earlier than those without mental illness, largely from cardiovascular disease due to high rates of smoking and obesity. The objective of this study was to determine whether the metabolic effects of postcessation weight gain among smokers with serious mental illness attenuated the cardiovascular benefit of tobacco abstinence.
  
  
  METHODS
  A subgroup analysis was conducted of 65 outpatient smokers with DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder from 10 community mental health centers in 6 states who enrolled between March 2008-April 2012 and completed a trial of varenicline for tobacco abstinence. The intervention included a 12-week open-label phase with varenicline followed by a 40-week randomized, placebo-controlled phase in 87 participants who achieved 12-week abstinence. Main outcome measures were smoking status and change from baseline in weight and 10-year Framingham cardiovascular risk score at end of intervention (week 52).
  
  
  RESULTS
  At week 52, 65 participants completed follow-up (33 abstinent; 32 relapsed). At baseline, the 2 groups did not differ in body mass index (mean = 31 kg/m(2)), blood pressure, serum glucose, or diagnoses of diabetes (31%) and hypertension (34%). Abstinent participants were older and had a higher mean baseline Framingham risk score (14.2% vs 10.3%, P = .002). At week 52, abstinent participants gained more weight than relapsed participants (4.8 vs 1.2 kg, P = .048) and, as a result of quitting smoking, had a greater reduction in Framingham risk score (-7.6% vs 0.0%, P < .001). There was no effect of study drug assignment on weight or Framingham risk score.
  
  
  CONCLUSIONS
  Sustained tobacco abstinence reduced 10-year cardiovascular risk in outpatients with serious mental illness despite significant postcessation weight gain and high prevalence of obesity, diabetes, and hypertension.
  
  
  BACKGROUND
  Clinicaltrials.gov identifier: NCT00621777.
authors.affiliation: Massachusetts General Hospital, 50 Staniford St, 9th Fl, Boston, MA 02114 athorndike@partners.org.
authors.forename: Anne N
authors.initials: AN
authors.lastname: Thorndike
authors.forename: Eric D
authors.initials: ED
authors.lastname: Achtyes
authors.forename: Corinne
authors.initials: C
authors.lastname: Cather
authors.forename: Sarah
authors.initials: S
authors.lastname: Pratt
authors.forename: Gladys N
authors.initials: GN
authors.lastname: Pachas
authors.forename: Susanne S
authors.initials: SS
authors.lastname: Hoeppner
authors.forename: A Eden
authors.initials: AE
authors.lastname: Evins
mesh_terms: D002318:Cardiovascular Diseases / Q000150:complications* / Q000209:etiology*; D003920:Diabetes Mellitus / Q000209:etiology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000209:etiology; D008297:Male; D001523:Mental Disorders / Q000150:complications*; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000209:etiology; D012074:Remission Induction / Q000379:methods; D016540:Smoking Cessation / Q000379:methods*; D000068580:Varenicline / Q000627:therapeutic use; D015430:Weight Gain
chemical_list: D000068580:Varenicline